Involvement of p53 mutation and mismatch repair proteins dysregulation in NNK-induced malignant transformation of human bronchial epithelial cells

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Shen, Ying ^a   Zhang, Shuilian ^a   Huang, Xiaobin ^a   Chen, Kailin ^a   Shen, Jing ^a   Wang, Zhengyang ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; ARGININE; HISTIDINE; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN P53; 4-(N-METHYL-N-NITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; MLH1 PROTEIN, HUMAN; NITROSAMINE; NUCLEAR PROTEIN; PMS2 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BRONCHUS MUCOSA; CELL CYCLE ARREST; CELL PROLIFERATION; CODON; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; DOWN REGULATION; EPITHELIUM CELL; GENE; GENE MUTATION; GENOME; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PROTEIN EXPRESSION; TRANSACTIVATION; TRANSFORMED CELL; WILD TYPE; ADVERSE EFFECTS; BIOSYNTHESIS; BRONCHUS; CELL TRANSFORMATION; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GENOMIC INSTABILITY; MISMATCH REPAIR; NEOPLASM; PATHOLOGY; TOBACCO;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; APOPTOSIS; BRONCHI; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; NITROSAMINES; NUCLEAR PROTEINS; TOBACCO; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907386611     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/920275     Document Type: Article

References (45)

1. S. S. Hecht, "Tobacco smoke carcinogens and lung cancer," Journal of the National Cancer Institute, vol. 91, no. 14, pp. 1194-1210, 1999.
2. D. Hoffmann, A. Rivenson, and S. S. Hecht, "The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung," Critical Reviews in Toxicology, vol. 26, no. 2, pp. 199-211, 1996.
3. G. Akopyan and B. Bonavida, "Understanding tobacco smoke carcinogen NNK and lung tumorigenesis," International Journal of Oncology, vol. 29, no. 4, pp. 745-752, 2006.
4. P. A. J. Muller and K. H. Vousden, "P53 mutations in cancer," Nature Cell Biology, vol. 15, no. 1, pp. 2-8, 2013.
5. S. Toyooka, T. Tsuda, and A. F. Gazdar, "The TP53 gene, tobacco exposure, and lung cancer," Human Mutation, vol. 21, no. 3, pp. 229-239, 2003.
6. A. Mogi and H. Kuwano, "TP53 mutations in nonsmall cell lung cancer," Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 583929, 9 pages, 2011.
7. G. P. Pfeifer, M. F. Denissenko, M. Olivier, N. Tretyakova, S. S. Hecht, and P. Hainaut, "Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers," Oncogene, vol. 21, no. 48, pp. 7435-7451, 2002.
8. J. Cloutier, R. Drouin, M. Weinfeld, T. R. O'Connor, and A. Castonguay, "Characterization and mapping of DNA damage induced by reactivemetabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) at nucleotide resolution in human genomic DNA," Journal of Molecular Biology, vol. 313, no. 3, pp. 539-557, 2001.
9. M. Rajesh, G. Wang, R. Jones, and N. Tretyakova, "Stable isotope labeling-mass spectrometry analysis of methyl- and pyridyloxobutyl-guanine adducts of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone in p53-derived DNA sequences," Biochemistry, vol. 44, no. 6, pp. 2197-2207, 2005.
10. P. Hsieh and K. Yamane, "DNA mismatch repair: molecular mechanism, cancer, and ageing," Mechanisms of Ageing and Development, vol. 129, no. 7-8, pp. 391-407, 2008.
11. J. Chang, Y. Chen, C. Chen, J. Chen, S. Chen, and Y. Wang, "Correlation of genetic instability withmismatch repair protein expression and p53 mutations in non-small cell lung cancer," Clinical Cancer Research, vol. 6, no. 5, pp. 1639-1646, 2000.
12. J. Markovic, J. Stojsic, S. Zunic, S. Ruzdijic, and N. Tanic, "Genomic instability in patients with non-small cell lung cancer assessed by the arbitrarily primed polymerase chain reaction," Cancer Investigation, vol. 26, no. 3, pp. 262-268, 2008.
13. Y. Wang, Y. Lu, R. Tseng et al., "Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples," Journal of Clinical Investigation, vol. 111, no. 6, pp. 887-895, 2003.
14. H. Zhou, G. M. Calaf, and T. K. Hei, "Malignant transformation of human bronchial epithelial cells with the tobaccospecific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone," International Journal of Cancer, vol. 106, no. 6, pp. 821-826, 2003.
15. Y. Demizu, R. Sasaki, D. Trachootham et al., "Alterations of cellular redox state during NNK-induced malignant transformation and resistance to radiation," Antioxidants and Redox Signaling, vol. 10, no. 5, pp. 951-961, 2008.
16. G. Mennecier, L. N. Torres, B. Cogliati et al., "Chronic exposure of lung alveolar epithelial type II cells to tobacco-specific carcinogen nnk results in malignant transformation: a new in vitro lung carcinogenesismodel," Molecular Carcinogenesis, vol. 53, no. 5, pp. 392-402, 2014.
17. H. Yamamoto, F. Itoh, H. Nakamura et al., "Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability," Cancer Research, vol. 61, no. 7, pp. 3139-3144, 2001.
18. C. R. Boland, S. N. Thibodeau, S. R. Hamilton et al., "A National Cancer Instituteworkshop onmicrosatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer," Cancer Research, vol. 58, no. 22, pp. 5248-5257, 1998.
19. C. An, I. Choi, J. C. Yao et al., "Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma," Clinical Cancer Research, vol. 11, no. 2, pp. 656-663, 2005.
20. J. L. Ko, Y. W. Cheng, S. L. Chang, J. M. Su, C. Y. Chen, and H. Lee, "mRNA expression is a favorable prognostic factor in non-small-cell lung cancer," International Journal of Cancer, vol. 89, no. 3, pp. 265-270, 2000.
21. H. Qi, H. Zhu, M. Lou et al., "Interferon regulatory factor 1 transactivates expression of human DNA polymerase η in response to carcinogen N-methyl-N′-nitro-N-nitrosoguanidine," The Journal of Biological Chemistry, vol. 287, no. 16, pp. 12622-12633, 2012.
22. S. Negrini, V. G. Gorgoulis, and T. D. Halazonetis, "Genomic instability-an evolving hallmark of cancer," Nature Reviews Molecular Cell Biology, vol. 11, no. 3, pp. 220-228, 2010.
23. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646-674, 2011.
24. L. A. Aaltonen and P. Peltomaki, "Genes involved in hereditary nonpolyposis colorectal carcinoma," Anticancer Research, vol. 14, no. 4B, pp. 1657-1660, 1994.
25. P. Taverna, L. Liu, A. J. Hanson, A. Monks, and S. L. Gerson, "Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen," Cancer Chemotherapy and Pharmacology, vol. 46, no. 6, pp. 507-516, 2000.
26. M. F. Kane, M. Loda, G. M. Gaida et al., "Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines," Cancer Research, vol. 57, no. 5, pp. 808-811, 1997.
27. S. B. Simpkins, T. Bocker, E. M. Swisher et al., "MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers," Human Molecular Genetics, vol. 8, no. 4, pp. 661-666, 1999.
28. Y. Kondo, L. Shen, and J. J. Issa, "Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer," Molecular and Cellular Biology, vol. 23, no. 1, pp. 206-215, 2003.
29. H. Chen, Y. Yan, T. L. Davidson, Y. Shinkai, and M. Costa, "Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells," Cancer Research, vol. 66, no. 18, pp. 9009-9016, 2006.
30. H. Sun, X. Zhou, H. Chen, Q. Li, and M. Costa, "Modulation of histone methylation and MLH1 gene silencing by hexavalent chromium," Toxicology and Applied Pharmacology, vol. 237, no. 3, pp. 258-266, 2009.
31. J. Jiricny, "The multifaceted mismatch-repair system," Nature Reviews Molecular Cell Biology, vol. 7, no. 5, pp. 335-346, 2006.
32. K. Truninger, M. Menigatti, J. Luz et al., "Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer," Gastroenterology, vol. 128, no. 5, pp. 1160-1171, 2005.
33. S. Gill, N. M. Lindor, L. J. Burgart et al., "Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation," Clinical Cancer Research, vol. 11, no. 18, pp. 6466-6471, 2005.
34. T. Okuda, K. Kawakami, K. Ishiguro, M. Oda, K. Omura, and G. Watanabe, "The profile of hMLH1 methylation and microsatellite instability in colorectal and non-small cell lung cancer," International Journal ofMolecularMedicine, vol. 15, no. 1, pp. 85-90, 2005.
35. S. Dacic, D. Lomago, J. L. Hunt, A. Sepulveda, and S. A. Yousem, "Microsatellite instability is uncommon in lymphoepitheliomalike carcinoma of the lung," The American Journal of Clinical Pathology, vol. 127, no. 2, pp. 282-286, 2007.
36. T. J. Seng, N. Currey, W. A. Cooper et al., "DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma," British Journal of Cancer, vol. 99, no. 2, pp. 375-382, 2008.
37. T. Soussi and K. G. Wiman, "Shaping genetic alterations in human cancer: the p53 mutation paradigm," Cancer Cell, vol. 12, no. 4, pp. 303-312, 2007.
38. P. V. Zacharatos, V. G. Gorgoulis, A. Kotsinas et al., "Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment," Anticancer Research, vol. 19, no. 1, pp. 579-587, 1999.
39. K. P. Olive, D. A. Tuveson, Z. C. Ruhe et al., "Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome," Cell, vol. 119, no. 6, pp. 847-860, 2004.
40. F. Vikhanskaya, M. M. Siddique,M. K. Lee,M. Broggini, and K. Sabapathy, "Evaluation of the combined effect of p53 codon 72 polymorphism and hotspotmutations in response to anticancer drugs," Clinical Cancer Research, vol. 11, no. 12, pp. 4348-4356, 2005.
41. F. Vikhanskaya, M. K. Lee, M. Mazzoletti, M. Broggini, and K. Sabapathy, "Cancer-derived p53 mutants suppress p53-target gene expression-potential mechanism for gain of function of mutant p53," Nucleic Acids Research, vol. 35, no. 6, pp. 2093-2104, 2007.
42. P. Dong, M. Tada, J. Hamada, A. Nakamura, T. Moriuchi, and N. Sakuragi, "p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells," Clinical and Experimental Metastasis, vol. 24, no. 6, pp. 471-483, 2007.
43. P. A. J. Muller, K. H. Vousden, and J. C. Norman, "p53 and its mutants in tumor cell migration and invasion," Journal of Cell Biology, vol. 192, no. 2, pp. 209-218, 2011.
44. M. L. Agarwal, A. Agarwal, W. R. Taylor, and G. R. Stark, "p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts," Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 18, pp. 8493-8497, 1995.
45. B. Yang, P. J. Stambrook, and S. D. Markowitz, "Wild-type p53 demonstrates functional dominance in a human colon carcinoma cell line in which it induces reversible growth arrest," Clinical Cancer Research, vol. 2, no. 10, pp. 1639-1647, 1996.